Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

September 23, 2016

Study Completion Date

September 23, 2016

Conditions
Hemophilia A
Interventions
BIOLOGICAL

PEGylated Recombinant factor VIII (rFVIII)

Lyophilized powder and solvent for solution for injection

Trial Locations (22)

1527

SHAT of Oncohaematology Diseases, Sofia

8091

Universitaetsspital Zuerich, Zurich

9003

MHAT 'Sv. Marina', EAD, Varna

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

17033

Penn State Milton S. Hershey Medical Center, Hershey

29010

Hospital Regional Universitario de Malaga, Málaga

32610

University of Florida College of Medicine, Gainesville

40202

University of Louisville, Louisville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46026

Hospital Universitari i Politecnic La Fe, Valencia

61614

Bleeding and Clotting Disorders Institute, Peoria

64108

Children's Mercy Hospitals & Clinics, Kansas City

79044

SI Institute of Blood Pathology and Transfusion Medicine of AMSU, Lviv

84132

University of Utah Health Sciences Center, Salt Lake City

98104

University of Washington, Seattle

610000

"FSHI Kirov SR Institute of Hematology and Blood Transfusion FMBA", Kirov

08661

Vilnius University Hospital Santariskiu Clinics, Public Institution, Vilnius

1105 AZ

Academisch Medisch Centrum, Amsterdam

07010

Hospital Universitari Son Espases, Palma de Mallorca

NW3 2QG

Royal Free Hospital, London

WC1N 3JH

Great Ormond Street Hospital for Children, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT01913405 - Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures | Biotech Hunter | Biotech Hunter